Enfortumab Vedotin + Pembrolizumab for Bladder Cancer

This trial explores whether combining two treatments, enfortumab vedotin (an antibody-drug conjugate) and pembrolizumab (an immunotherapy drug), can help people with muscle-invasive bladder cancer preserve their bladder. Typically, patients with this cancer type undergo chemotherapy and bladder removal surgery. However, the trial seeks alternatives for those unable or unwilling to have surgery. It seeks participants with muscle-invasive bladder cancer who are eligible for bladder surgery but may wish to explore other options. Participants will receive regular infusions of the study drugs and will have their health closely monitored throughout the trial. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group of people.

The trial protocol does not specify if you need to stop taking your current medications. However, if you are on systemic steroid therapy or immunosuppressive therapy, you may need to stop or adjust these, as they are not allowed within 7 days before the first dose of the study treatment.

Research has shown that the combination of enfortumab vedotin and pembrolizumab is generally well-tolerated by patients. In studies involving individuals with advanced bladder cancer, this treatment produced manageable side effects and promising results. The safety profile was deemed acceptable, indicating that while some side effects occurred, they were not severe for most patients.

One study found that this combination treatment extended patients' lives compared to previous treatments. This finding suggests that the treatment is not only effective but also safe enough for patients to continue without major issues.

Enfortumab Vedotin combined with Pembrolizumab is unique because it targets bladder cancer in a dual-action approach. Enfortumab Vedotin is an antibody-drug conjugate that delivers a powerful chemotherapy agent directly to cancer cells, potentially increasing effectiveness while reducing side effects. Pembrolizumab, on the other hand, is an immune checkpoint inhibitor that helps the immune system better recognize and attack cancer cells. This combination aims to both directly kill cancer cells and enhance the body's immune response, which could offer a more comprehensive attack on the tumor compared to traditional chemotherapy alone. Researchers are excited because this approach may improve outcomes for bladder cancer patients who have limited options with current treatments.

Research has shown that combining enfortumab vedotin and pembrolizumab holds promise for treating advanced bladder cancer. In this trial, participants will receive enfortumab vedotin on days 1 and 8 of each 21-day cycle and pembrolizumab on day 1 of each cycle. Studies have found that this combination can nearly double patient survival, with some living over two years longer than expected. Specifically, one study showed that 68% of patients experienced tumor shrinkage, indicating the treatment's effectiveness for many. Another study found that patients lived for an average of 34 months, which is notable for this type of cancer. These findings suggest that enfortumab vedotin with pembrolizumab could be an effective option, especially for those seeking to avoid surgery.¹²³⁴⁶